Bisphosphonate drugs are a go-to treatment for osteoporosis, but they come with a significant risk of triggering an atypical femoral fracture, especially if you use them for more than five years. Their use is controversial, particularly because bone mineral density isn’t an accurate measure of bone strength and fracture risk.
And yet, bisphosphonate drugs are the first-line therapy for the prevention and treatment of osteoporosis, with 14.7 million prescriptions written annually in the U.S.[i]
